This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

A Deep Dive Into Phenylketonuria (PKU) - Exploring New Approaches by BioMarin, Homology, Rubius, and Moderna

Ticker(s): BMRN, MRNA, RUBY, FIXX

Who's the expert?

Name: Dr Barbara Burton - MD

Institution: Northwestern

  • Professor of Pediatrics (Genetics, Birth Defects, and Metabolism) at Northwestern University Feinberg School of Medicine & Director, PKU Program.
  • Currently manages 320 patients with Phenylketonuria (PKU).
  • Participated in numerous clinical trials of new therapies for metabolic disorders including PKU, lysosomal storage disorders and fatty acid oxidation defects and has authored over 200 articles in the peer-reviewed literature.

Interview Goal
To dig into the PKU treatment landscape and examine where the competing therapies from  BioMarin, Homology, Rubius, and Moderna stand. This call will discuss:
  • PALYNZIQ® (pegvaliase-pqpz) Injection for PKU (BMRN)
  • HMI-102 Gene Therapy (FIXX)
  • RTX-134 (RUBY)
  • mRNA-3283(MRNA)

Are You Interested In These Questions?



Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.